BriaCell Therapeutics Corp. (BCTX)

BriaCell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is August - July.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Cash & Equivalents	10.49	0.86	21.25	41.04	57.27
Short-Term Investments	7.37	-	-	-	-
Cash & Short-Term Investments	17.87	0.86	21.25	41.04	57.27
Cash Growth	1972.44%	-95.94%	-48.22%	-28.34%	269412.38%
Other Receivables	-	0.74	-	0.02	0.01
Receivables	-	0.74	-	0.02	0.01
Prepaid Expenses	2.06	2.06	5.7	1.28	0.52
Total Current Assets	19.93	3.65	26.95	42.35	57.8
Property, Plant & Equipment	0.3	0.39	-	-	-
Long-Term Investments	0.52	0.42	0	0	0
Other Intangible Assets	0.18	0.2	0.22	0.23	0.25
Other Long-Term Assets	0.72	1.21	-	-	-
Total Assets	21.65	5.87	27.16	42.58	58.04
Accounts Payable	3.28	7.17	1.12	0.46	0.21
Accrued Expenses	0.69	0.29	0.68	0.48	0.34
Total Current Liabilities	3.98	7.46	1.8	0.94	0.56
Long-Term Debt	-	-	-	-	0.03
Other Long-Term Liabilities	0.34	1.1	29.14	31.31	29.79
Total Liabilities	4.32	8.56	30.94	32.25	30.37
Common Stock	101.74	72.17	69.59	65.59	54.77
Additional Paid-In Capital	-	-	-	-	2.18
Retained Earnings	-111.76	-85.44	-80.65	-60.35	-29.14
Comprehensive Income & Other	27.9	10.89	7.28	5.09	-0.14
Total Common Equity	17.88	-2.38	-3.78	10.33	27.67
Minority Interest	-0.55	-0.3	-	-	-
Shareholders' Equity	17.33	-2.68	-3.78	10.33	27.67
Total Liabilities & Equity	21.65	5.87	27.16	42.58	58.04
Total Debt	-	-	-	-	0.03
Net Cash (Debt)	17.87	0.86	21.25	41.04	57.24
Net Cash Growth	1972.44%	-95.94%	-48.22%	-28.30%	-
Net Cash Per Share	42.23	7.86	204.08	397.33	1899.79
Filing Date Shares Outstanding	1.88	0.12	0.11	0.1	0.1
Total Common Shares Outstanding	1.88	0.12	0.11	0.1	0.1
Working Capital	15.95	-3.81	25.15	41.41	57.24
Book Value Per Share	9.49	-19.54	-35.45	99.84	271.83
Tangible Book Value	17.7	-2.58	-3.99	10.1	27.43
Tangible Book Value Per Share	9.39	-21.18	-37.47	97.61	269.42
Machinery	0.46	0.46	-	-	-

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q